Study	Reason for exclusion
Agid 2010	Allocation: not a randomised controlled trial.
Bouchard 2000	Allocation: randomised. Participants: people with schizophrenia. Interventions: oral risperidone versus conventional antipsychotic drugs (not depot risperidone).
Canas 2010	Allocation: not randomised; review article.
DeMartinis 2012a	Allocation: randomised. Participants: people with schizophrenia. Intervention: not depot risperidone. 1. PF‐02545920: 5 mg and 15 mg (titrated fixed doses. 3 mg (titrated). 2. Risperidone (oral) twice a day: 3 mg titrated. 3. Placebo.
Eerdekens 2002 a	Allocation: not randomised; open‐label.
Eerdekens 2002 b	Allocation: not randomised; review.
Gallhofer 1995	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol or fluphenazine, not depot risperidone.
Geffen 2012	Allocation: randomised. Participants: people with chronic schizophrenia. Intervention: BL‐1020: 10 mg/day, BL‐1020: 20 ‐ 30 mg/day, risperidone (oral): 2 ‐ 8 mg/day, placebo, not depot risperidone
Gefvert 2001	Allocation: not a randomised controlled trial.
Kogeorgos 1995	Allocation: randomised. Participants: people with schizophrenia. Interventions: sulpiride or risperidone versus chlorpromazine, trifluoperazine or haloperidol, not depot risperidone.
Koola 2009	Allocation: randomised. Participants: people with schizophrenia. Intervention: long‐acting injectable risperidone or oral atypical antipsychotics. Outcomes: no useable data, only levels of insight and relapse at baseline.
Lindenmayer 1995	Allocation: non‐randomised comparison of two samples taken from randomised trials.
Litman 2014	Allocation: randomised. Participants: people with schizophrenia. Intervention: AZD8529 40 mg, risperidone (oral) 4 mg, or placebo, not depot risperidone.
Littrell 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine, not depot risperidone.
Liu 2014f	Allocation: randomised. Participants: people with early stage schizophrenia. Intervention: minocycline or placebo, not depot risperidone.
Lloyd 2010	Allocation: not randomised.
Macfadden 2008	Allocation: randomised. Participants: people with schizophrenia. Interventions: 25 mg or 50 mg of risperidone depot no other comparison group (post‐hoc analysis from another study).
McClure 2009a	Allocation: randomised. Participnats: females with schizotypal personality disorder, not schizophrenia.
Pikalov 2012a	Allocation: not randomised, a review of studies.
Procyshyn 2010	Allocation: non‐random, pilot study.
Ritchie 1999	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine, not depot risperidone.
Robinson 2000	Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine, not depot risperidone.
Schmechtig 2010	Allocation: randomised. Participants: people with subclinical levels of schizophrenia‐like symptoms (high schizotypy). Intervention: nicotine, risperidone, amisulpride or placebo, not depot risperidone.
Simpson 2006	Allocation: randomised. Participants: people with schizophrenia. Interventions: two doses of depot risperidone, no control.
Vaughan 2000	Allocation: randomised. Participants: people with schizophrenia. Interventions: not a drug trial, study of effect of community treatment orders.
Verma 2010	Interventions: participants switched to depot risperidone with no other comparison group.
Weiden 2007	Allocation: randomised to recommendation of treatment.
Wiffen 2010	Allocation: non‐randomised; depot risperidone was the only intervention.